Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines.

Literature DB >> 33540942

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines.

Basmah N Aldosari¹, Iman M Alfagih¹, Alanood S Almurshedi¹.

Abstract

There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer.

Entities: Chemical

Keywords: adjuvant; cancer immunotherapy; cationic lipids; delivery system; lipid nanoparticles; mRNA; nanotechnology; nucleic acid; vaccines

Year: 2021 PMID： 33540942 PMCID： PMC7913163 DOI： 10.3390/pharmaceutics13020206

Source DB: PubMed Journal: Pharmaceutics ISSN： 1999-4923 Impact factor: 6.321

142 in total

Review 1. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors: Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal: Mol Ther Date: 2019-02-07 Impact factor: 11.454

2. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

Authors: Adam Judge; Kevin McClintock; Janet R Phelps; Ian Maclachlan
Journal: Mol Ther Date: 2005-11-07 Impact factor: 11.454

3. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

Authors: Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci
Journal: Nature Date: 2020-07-29 Impact factor: 49.962

4. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors: Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal: Mol Ther Date: 2010-05-11 Impact factor: 11.454

5. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.

Authors: Sean C Semple; Troy O Harasym; Kathy A Clow; Steven M Ansell; Sandra K Klimuk; Michael J Hope
Journal: J Pharmacol Exp Ther Date: 2004-11-03 Impact factor: 4.030

6. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface.

Authors: Anna Salvati; Andrzej S Pitek; Marco P Monopoli; Kanlaya Prapainop; Francesca Baldelli Bombelli; Delyan R Hristov; Philip M Kelly; Christoffer Åberg; Eugene Mahon; Kenneth A Dawson
Journal: Nat Nanotechnol Date: 2013-01-20 Impact factor: 39.213

Review 7. Therapeutic cancer vaccines.

Authors: Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal: J Clin Invest Date: 2015-07-27 Impact factor: 14.808

8. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Authors: Shinu John; Olga Yuzhakov; Angela Woods; Jessica Deterling; Kimberly Hassett; Christine A Shaw; Giuseppe Ciaramella
Journal: Vaccine Date: 2018-02-15 Impact factor: 3.641

Review 9. Opportunities and Challenges in the Delivery of mRNA-based Vaccines.

Authors: Abishek Wadhwa; Anas Aljabbari; Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal: Pharmaceutics Date: 2020-01-28 Impact factor: 6.321

10. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.

Authors: Jing Lu; Guoliang Lu; Shudan Tan; Jia Xia; Hualong Xiong; Xiaofei Yu; Qingqing Qi; Xiang Yu; Li Li; Hang Yu; Ningshao Xia; Tianying Zhang; Yingjie Xu; Jinzhong Lin
Journal: Cell Res Date: 2020-08-17 Impact factor: 25.617

26 in total

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines.

Review 1. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

2. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

3. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

4. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

5. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.

6. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface.

Review 7. Therapeutic cancer vaccines.

8. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Review 9. Opportunities and Challenges in the Delivery of mRNA-based Vaccines.

10. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.

Review 1. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.

Review 2. mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Review 3. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids.

Review 4. Nanomaterials Synthesis through Microfluidic Methods: An Updated Overview.

Review 5. Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments.

Review 6. Synthesis and Potential Applications of Lipid Nanoparticles in Medicine.

Review 7. New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.

Review 8. Advanced Microfluidic Technologies for Lipid Nano-Microsystems from Synthesis to Biological Application.

Review 9. mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.

Review 10. Antisense Oligonucleotide-Based Therapy of Viral Infections.